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Abstract
Introduction. Numerous data indicate that luteinizing hormone and/or chorionic gonadotropin (LH/CG) exert 
direct actions on the adrenal cortex and are involved in the adrenal pathology. However, the immunohisto-
chemical studies on the expression of LH/CG receptors (LH/CGR) in the human adrenal cortex and in the 
adrenocortical tumors are scarce. 
Material and methods. Paraffin sections of samples of 6 human non-neoplastic adrenal cortex and 25 adreno-
cortical tumors were immunostained with anti-LH/CGR polyclonal antibody.
Results. All zones of the human non-neoplastic adrenal cortex present a positive immunoreaction with anti-LH/ 
/CGR antibody showing the strongest reaction in cell membranes. The LH/CGR immunostaining in the vast ma-
jority of hormonally non-functioning adenomas and in all hormone-secreting adenomas does not differ from the 
non-neoplastic adrenal cortex. In contrast to non-neoplastic adrenal cortex and benign adenomas, in adrenocor-
tical cancers the immunostaining with anti-LH/CGR antibody behaves differently. The immunopositive material 
is almost totally filling the cytoplasm of the cells but the immunopositivity of cell membranes is weak or lacking.
Conclusions. The data presented in our study show that the expression of LH/CGR in adrenocortical tumors is 
not ectopic but eutopic. The immunohistochemical examination of LH/CGR may be useful in the differentiation 
between benign and malignant lesions in the adrenal cortex. Moreover, the loss of membrane localization of 
LH/CGR in adrenocortical cancer suggests the alteration of receptors’ function. (Folia Histochemica et Cytobi-
ologica 2019, Vol. 57, No. 1, 23–27)
Key words: adrenal cortex; adrenocortical adenomas; adrenocortical cancer;  
luteinizing hormone/chorionic gonadotropin receptor
Introduction
The data indicating the direct actions of gonadotro-
pins on the adrenal gland were published as early as 
in the sixties of the 20th century [1–3]. The quoted 
authors observed the morphological changes in the 
adrenal cortex of the rat under the influence of ex-
ogenous administration of LH and/or FSH. Since 
the model of gonadectomized-hypophysectomized 
animals was used in the experiments, the mediation 
of gonadal steroids could be excluded.
In the forthcoming years the gonadotropin recep-
tors’ structure was elucidated as membrane G-pro-
tein-coupled elements possessing seven transmem-
brane domains [4]. The further studies showed the pres-
ence of lutropin/chorionic gonadotropins receptors 
(LH/CGR) in the normal human adrenal cortex [5, 6] 
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in human adrenocortical aldosterone-secreting [6–8] 
or cortisol-secreting adenomas [9–10] and adreno-
cortical cancers [11]. The functional LH/CGR were 
also found in human adrenocortical cancer cell line 
H 295R cells [12]. The data on LH/CGR in adre-
nal tissues were collected mostly using molecular 
biology techniques [6–11] but no systemic immuno-
histochemical studies of adrenocortical tumors and 
non–tumoral human adrenal cortex are available.
Material and methods 
Samples of adrenal glands. The archival material of 25 sur-
gically excised adrenal tumors stored in paraffin blocks was 
studied. The detailed presentation of material was shown 
in Table 1. In addition 6 non-tumoral adrenal glands were 
studied. Two of them were removed from patients suffering 
from renal cancers during the surgical excision of the affect-
ed kidney, one was excised together with pheochromocytoma 
tumor, and 3 were diagnosed as adrenocortical hyperplasia. 
The study was approved by the Ethical Committee of the 
Medical University of Lodz, decision RNN/335/17/KE dated 
21 November 2017.
Immunohistochemistry. Paraffin sections were immunos-
tained with anti-LH/CGR polyclonal antibody PA 1552 
(Boster Biologicals Technologies, Pleasanton, CA, USA). 
This antibody binds the N-terminal part of LH/CGR (127-
143 aa). The slides were incubated with antibody (1:150) for 
24 h at 4oC The visualization of immunostaining was per-
formed using Envision kit (DAKO, Glostrup, Denmark) with 
the use of 3,3’ diaminobenzidine (DAB) as chromogen. For 
a positive control, a biopsy sample of the human testis was 
immunostained (Fig. 1A). For a negative control, the prima-
ry antibody was omitted in the immunostaining procedure.
Statistical analysis. Since we present only qualitative de-
scriptions no statistical analysis was performed.
Results
All zones of the human non-neoplastic adrenal cortex 
show a positive immunoreaction with anti-LH/CGR 
antibody. In zona glomerulosa and zona fasciculata the 
strongest immunoreaction is visible in cell membranes 
(Fig. 1B and C). On the other hand, the cytoplasmic 
area of adrenocortical cells is mostly empty because of 
the washing out of the fat deposits. A scarce residual 
immunostaining was also present. In zona reticularis 
the distribution of immunoreaction is similar but 
a part of cells contain the abundant immunoreactive 
material in their cytoplasm (Fig. 1D).
The LH/CGR immunostaining in the vast majority 
(10/11) of hormonally non-functioning adenomas 
and in all cortisol-secreting adenomas does not differ 
from the non-neoplastic glomerulosa and fasciculata 
zones (Fig. 2A and B). In one case of non-function-
ing adenoma the loss of immunoreaction within cell 
membranes and homogenous immunoreaction of 
cytoplasm was noticed. In aldosterone-producing 
adenomas (Conn’s syndrome) the immunostaining 
of cell membranes does not differ from normal zona 
glomerulosa, but the density of the immunoreaction 
of cytoplasm is more variable (Fig. 2C). 
In contrast to non-neoplastic adrenal cortex and 
benign adenomas, in adrenocortical cancers the im-
munostaining with anti-LH/CGR antibody behaves 
differently. The immunopositive material of variable 
intensity is almost totally filling the cell cytoplasm. In 
contrast, the immunopositivity of cell membranes is 
very weak or lacking except one case (Fig. 2D).
Discussion
The expression of LH/CGR in non-neoplastic ad-
renal cortex and in certain adrenal tumors is well 
established in many studies conducted with molecular 
Table 1. The source of adrenocortical samples included in the study
Histopathological diagnosis Clinical status No of patients
Normal adrenal cortex No alterations of the adrenal function 3
Adrenocortical hyperplasia No alterations of the adrenal function 3
Adrenocortical adenoma Non-functioning tumor 11
Adrenocortical adenoma Conn’s syndrome 5
Adrenocortical adenoma Cushing’s syndrome 4
Adrenocortical cancer Malignant tumor, Cushing’s syndrome 1
Adrenocortical cancer Non-functioning malignant tumor 4
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biology techniques [4–13]. Although these studies 
present a high level of credibility, the information on 
precise tissue localization of LH/CGR is insufficient. 
Such data could be only supplied by morphological 
methods, mainly by immunohistochemistry. However, 
the immunohistochemical studies on the localization 
of LH/CGR in human adrenal cortex and adrenal tu-
mors are very scarce. Lesley et al. [14] investigated the 
presence of LH/CGR in the normal adrenal cortex of 
Rhesus macaque. They found, like we did in the hu-
mans, the positive immunoreactivity for LH/CGR in 
all adrenocortical zones. It is also worth recalling that 
we found similar immunopositivity in the normal ad-
renal cortex and adrenal tumors using the antibody for 
follicle stimulating hormone receptors (FSHRs) [15]. 
The LH/CGR immunopositivity which we found in 
adrenal benign and malignant tumors is in agreement 
with the results of previous studies [6–11]. Because the 
LH/CGR expression takes place also in the normal ad-
renal cortex, there is no reason to call them „ectopic”. 
The sharp difference in the topography of LH/CGR 
immunoreaction between the benign and malignant 
adrenal neoplasms is worth to underline. Because of 
that the immunohistochemical examination of LH/ 
/CGR seems to be useful in the differentiation be-
tween benign and malignant tumors of the adrenal 
cortex during the histopathological diagnosis. To our 
best knowledge, this finding has not been reported 
previously in the literature. However, our findings 
need to be confirmed on the larger material. Moreo-
ver, since LH/CGR belongs to membrane receptors, 
the partial or total loss of their membrane localization 
in adrenocortical cancers suggests the alteration of 
their function. The described loss of membrane local-
ization may reflect either down-regulation due to de-
creased expression of receptor gene at transcriptional 
level or the increased internalization of the receptor 
protein resulting from the ligand excess. The further 
studies, especially in vitro, concerning these possibil-
ities are needed. The role of the direct action of LH 
Figure 1. Immunostaining of LH/CGR in human non-neoplastic adrenocortical samples and testis. A. Positive control, human 
Leydig cells, 400×. B. Non-neoplastic adrenal cortex, glomerular zone, 200×. C. Non-neoplastic adrenal cortex, fascicular 
zone, 200×. D. Non-neoplastic adrenal cortex, reticular zone, 200×.
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in adrenal cortex is not fully understood. It probably 
acts as an additional regulator of steroidogenesis and 
adrenocortical cell growth. Its involvement in adren-
ocortical tumorigenesis has been also suggested and 
proved on certain animal models [16, 17].
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